PT -期刊文章盟保罗Preziosa AU -埃•m . Bouman盟Svenja Kiljan盟卡坦d Steenwijk AU -亚历山德罗代表我非盟-佩特拉Pouwels盟-玛丽亚·a·罗卡AU -马西莫菲利皮主持AU -吉尔茨基珀斯j。非盟-劳拉Jonkman TI -神经突密度解释皮质T1 / t2加权比多发性硬化症(2561)DP - 2021年4月13日第六TA -神经病学PG - 2561 - 96 IP - 15补充4099 - //www.ez-admanager.com/content/96/15_Supplement/2561.short 4100 - //www.ez-admanager.com/content/96/15_Supplement/2首页561.full所以Neurology2021 4月13;96 AB -目的:定义的比例的组织病理学衬底t1 (T1w)和t2加权(T2w)序列(即。T1w / T2w-ratio)在正常和退化皮质的多发性硬化症患者(pwm)通过执行结合事后MRI /组织病理学研究。背景:皮质损伤是临床相关的女士,但是可靠的核磁共振成像标记监测仍然是一个未满足的需求。T1w / T2w-ratio是临床可行的pwm核磁共振测量评估皮质异常,但其组织病理学衬底尚未完全阐明。设计/方法:15 pwm和十岁,sex-matched non-neurological原位控制(nNC)经历了事后3 t MRI与3 d T1w T2w序列,紧随其后的是大脑解剖。一百零五年石蜡包埋组织块(n = 49 pwm, n = 56 nNC)收集。组织区域匹配T1w / T2w-ratio地图区域皮质T1w / T2w-ratio获得。用免疫组织化学和银染色,皮质神经突髓鞘和密度的评估。关联T1w / T2w-ratio与组织学改变标记通过线性mixed-effects模型进行评估。结果:26皮质病变(单纯85%)被发现在24/49(51%)从pwm皮质区域。相比nNC的皮层,pwm的正常和退化皮质T1w / T2w-ratio明显降低(p = 0.045, 0.001)。 In PwMS, T1w/T2w-ratio was significantly lower in demyelinated vs normal-appearing cortex (p=0.007). In PwMS, neurite density was significantly lower in both normal-appearing and demyelinated cortices vs nNC (p=0.041 and 0.001), and in demyelinated vs normal-appearing cortex (p=0.048). Demyelinated cortex showed also significant lower myelin density vs normal-appearing cortex in both nNC and PwMS (p<0.001). Cortical T1w/T2w-ratio was positively associated with neurite density (β=3.464×10−2, p=0.004), whereas only a trend for myelin density was found (p=0.082).Conclusions: T1w/T2w-ratio is sensitive to MS cortical damage. Although both demyelination and neurite loss occur in MS cortex, T1w/T2w-ratio seems more strongly associated to cortical neurite than myelin density. T1w/T2w-ratio could be useful to investigate cortical damage in MS.Disclosure: Mr. Preziosa has nothing to disclose. Piet Bouman has received research support from MS Research Foundation. Svenja Kiljan has nothing to disclose. Martijn D Steenwijk has nothing to disclose. Alessandro Meani has nothing to disclose. Petra Pouwels has nothing to disclose. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva. The institution of Maria Assunta Rocca has received research support from Italian Ministry of Health, MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). The institution of Jeroen JG Geurts has received research support from Biogen, Celgene, Merck, Medday, and Novartis. Laura Jonkman has nothing to disclose.